Therapy Areas: Inflammatory Diseases
Genentech Data Demonstrate Efficacy, Safety, and Benefits of Ocrevus in Relapsing and Primary Progressive MS
18 April 2018 - - South San Francisco, California-based biotechnology company Genentech, a member of the Roche Group (SIX: RO) (OTCQX: RHHBY) will present new data on Ocrevus (ocrelizumab) during the 70th American Academy of Neurology annual meeting being held April 21-27 in Los Angeles, California, the company said.
These data will reinforce the efficacy and safety of Ocrevus and expand the clinical understanding of disability progression in multiple sclerosis (MS). Ocrevus data will show significant and sustained efficacy as well as benefits in cognition in people with relapsing multiple sclerosis (RMS).
The early impact of Ocrevus on biomarkers of inflammation and neurodegeneration in people with RMS will be shared for the first time through the OBOE (Ocrelizumab Biomarker Outcome Evaluation) study.
Additional presentations include updated safety analyses for Ocrevus, which will further inform and reinforce its continued favorable benefit-risk profile.
Neuroscience is a major focus of research and development at Genentech and Roche. Roche has more than a dozen investigational medicines in clinical development for diseases that include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, Parkinson's disease, and autism.
Genentech discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions.
Login
Username:

Password: